138 related articles for article (PubMed ID: 16685588)
1. Effects of estrogen receptor expression and histopathology on annual hazard rates of death from breast cancer.
Anderson WF; Chen BE; Jatoi I; Rosenberg PS
Breast Cancer Res Treat; 2006 Nov; 100(1):121-6. PubMed ID: 16685588
[TBL] [Abstract][Full Text] [Related]
2. Breast cancer mortality trends in the United States according to estrogen receptor status and age at diagnosis.
Jatoi I; Chen BE; Anderson WF; Rosenberg PS
J Clin Oncol; 2007 May; 25(13):1683-90. PubMed ID: 17404367
[TBL] [Abstract][Full Text] [Related]
3. Hormone receptor-negative breast cancer: undertreatment of patients over 80.
Weiss A; Noorbakhsh A; Tokin C; Chang D; Blair SL
Ann Surg Oncol; 2013 Oct; 20(10):3274-8. PubMed ID: 23838924
[TBL] [Abstract][Full Text] [Related]
4. Comparison of age distribution patterns for different histopathologic types of breast carcinoma.
Anderson WF; Pfeiffer RM; Dores GM; Sherman ME
Cancer Epidemiol Biomarkers Prev; 2006 Oct; 15(10):1899-905. PubMed ID: 17035397
[TBL] [Abstract][Full Text] [Related]
5. Contralateral prophylactic mastectomy provides no survival benefit in young women with estrogen receptor-negative breast cancer.
Pesce C; Liederbach E; Wang C; Lapin B; Winchester DJ; Yao K
Ann Surg Oncol; 2014 Oct; 21(10):3231-9. PubMed ID: 25081341
[TBL] [Abstract][Full Text] [Related]
6. Risk of mortality by histologic type of breast cancer among women aged 50 to 79 years.
Li CI; Moe RE; Daling JR
Arch Intern Med; 2003 Oct; 163(18):2149-53. PubMed ID: 14557212
[TBL] [Abstract][Full Text] [Related]
7. Survival outcomes in breast cancer patients with low estrogen/progesterone receptor expression.
Balduzzi A; Bagnardi V; Rotmensz N; Dellapasqua S; Montagna E; Cardillo A; Viale G; Veronesi P; Intra M; Luini A; Pruneri G; Mastropasqua G; Goldhirsch A; Colleoni M
Clin Breast Cancer; 2014 Aug; 14(4):258-64. PubMed ID: 24325948
[TBL] [Abstract][Full Text] [Related]
8. Distinct breast cancer incidence and prognostic patterns in the NCI's SEER program: suggesting a possible link between etiology and outcome.
Anderson WF; Jatoi I; Devesa SS
Breast Cancer Res Treat; 2005 Mar; 90(2):127-37. PubMed ID: 15803359
[TBL] [Abstract][Full Text] [Related]
9. Breast cancer proteomics reveals correlation between estrogen receptor status and differential phosphorylation of PGRMC1.
Neubauer H; Clare SE; Wozny W; Schwall GP; Poznanovic S; Stegmann W; Vogel U; Sotlar K; Wallwiener D; Kurek R; Fehm T; Cahill MA
Breast Cancer Res; 2008; 10(5):R85. PubMed ID: 18922159
[TBL] [Abstract][Full Text] [Related]
10. Retrospective analysis of risk factors for central nervous system metastases in operable breast cancer: effects of biologic subtype and Ki67 overexpression on survival.
Ishihara M; Mukai H; Nagai S; Onozawa M; Nihei K; Shimada T; Wada N
Oncology; 2013; 84(3):135-40. PubMed ID: 23235554
[TBL] [Abstract][Full Text] [Related]
11. Hazard of breast cancer-specific mortality among women with estrogen receptor-positive breast cancer after five years from diagnosis: implication for extended endocrine therapy.
Yu KD; Wu J; Shen ZZ; Shao ZM
J Clin Endocrinol Metab; 2012 Dec; 97(12):E2201-9. PubMed ID: 22993034
[TBL] [Abstract][Full Text] [Related]
12. Hormone receptor status and survival in a population-based cohort of patients with breast carcinoma.
Grann VR; Troxel AB; Zojwalla NJ; Jacobson JS; Hershman D; Neugut AI
Cancer; 2005 Jun; 103(11):2241-51. PubMed ID: 15844176
[TBL] [Abstract][Full Text] [Related]
13. Comparison of age-specific incidence rate patterns for different histopathologic types of breast carcinoma.
Anderson WF; Chu KC; Chang S; Sherman ME
Cancer Epidemiol Biomarkers Prev; 2004 Jul; 13(7):1128-35. PubMed ID: 15247123
[TBL] [Abstract][Full Text] [Related]
14. Prognostic markers for invasive micropapillary carcinoma of the breast: a population-based analysis.
Chen AC; Paulino AC; Schwartz MR; Rodriguez AA; Bass BL; Chang JC; Teh BS
Clin Breast Cancer; 2013 Apr; 13(2):133-9. PubMed ID: 23246269
[TBL] [Abstract][Full Text] [Related]
15. Clinicopathological analyses of triple negative breast cancer using surveillance data from the Registration Committee of the Japanese Breast Cancer Society.
Iwase H; Kurebayashi J; Tsuda H; Ohta T; Kurosumi M; Miyamoto K; Yamamoto Y; Iwase T
Breast Cancer; 2010 Apr; 17(2):118-24. PubMed ID: 19466512
[TBL] [Abstract][Full Text] [Related]
16. Immunohistochemically defined subtypes and outcome of apocrine breast cancer.
Dellapasqua S; Maisonneuve P; Viale G; Pruneri G; Mazzarol G; Ghisini R; Mazza M; Iorfida M; Rotmensz N; Veronesi P; Luini A; Goldhirsch A; Colleoni M
Clin Breast Cancer; 2013 Apr; 13(2):95-102. PubMed ID: 23245877
[TBL] [Abstract][Full Text] [Related]
17. Breast cancer as heterogeneous disease: contributing factors and carcinogenesis mechanisms.
Kravchenko J; Akushevich I; Seewaldt VL; Abernethy AP; Lyerly HK
Breast Cancer Res Treat; 2011 Jul; 128(2):483-93. PubMed ID: 21225455
[TBL] [Abstract][Full Text] [Related]
18. Placental weight and mortality in premenopausal breast cancer by tumor characteristics.
Hajiebrahimi MH; Bahmanyar S; Lambe M; Adolfsson J; Fornander T; Wärnberg F; Cnattingius S
Breast Cancer Res Treat; 2013 Jan; 137(1):297-305. PubMed ID: 23149466
[TBL] [Abstract][Full Text] [Related]
19. Validity of the proliferation markers Ki67, TOP2A, and RacGAP1 in molecular subgroups of breast cancer.
Milde-Langosch K; Karn T; Müller V; Witzel I; Rody A; Schmidt M; Wirtz RM
Breast Cancer Res Treat; 2013 Jan; 137(1):57-67. PubMed ID: 23135572
[TBL] [Abstract][Full Text] [Related]
20. Patterns of recurrence in the basal and non-basal subtypes of triple-negative breast cancers.
Nofech-Mozes S; Trudeau M; Kahn HK; Dent R; Rawlinson E; Sun P; Narod SA; Hanna WM
Breast Cancer Res Treat; 2009 Nov; 118(1):131-7. PubMed ID: 19189211
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
